Register to the Webinar
Session #1 - September 24th, 9am CET - 4pm JST: Click here to register
Session #2 - September 24th, 5pm CET - 11am EST: Click here to register
Agenda Highlights
In this webinar, we explore our vision for the future of drug discovery – one where generative AI, robotic synthesis, and intelligent orchestration converge to radically accelerate the pace of innovation. By tightly integrating de novo molecule design with real-time synthesis feasibility, this new approach transforms how ideas move from concept to compound:
- How the integration of GenAI and robotics is reshaping molecular design, synthesis, and testing
- How de novo designed molecules can now be optimized for robotics synthesis
- How AI-driven orchestration automates decision-making – from route selection to reaction batching to robotic execution
- Lessons learned from recent real-world projects, where hundreds of complex molecules were designed and synthesized with minimal human intervention.
- The strategic shifts needed for R&D teams to fully leverage this new paradigm.
Whether you're a chemist, a computational scientist, robotics expert or R&D decision-maker, this session offers both inspiration and practical guidance on building the next generation of discovery workflows.
Speakers
Quentin Perron
Chief Scientific Officer & Co-founder, Iktos
Quentin Perron is a medicinal chemist by training. He holds a PhD in organometallic chemistry from the University of Geneva. During his post-doc fellowship at UCLA he worked on the total synthesis of Brasillicardin A, a complex natural molecule known for having a potent immunosuppressive activity. After working as a medicinal chemist in CNS indications at Laboratoires Servier, he switched to data science and chemoinformatics at Quinten, a company specialized in data science services. In 2016, with his business partners Yann Gaston-Mathé and Nicolas Do Huu, he co-founded Iktos, a start-up company developing AI technologies for new drug design. He is now the CSO of the company.
Franck Le Vaillant
Senior Scientist - Deputy Lab Head
Franck has a Master degree from the Ecole Nationale Supérieure de Chimie de Montpellier. From 2014 to 2018, he carried out his PhD studies at EPFL under the supervision of Prof. Jérôme Waser, during which he explored photoredox-catalyzed functionalizations of radicals using hypervalent iodine reagents. He then moved as SNF-postdoctoral fellow in the group of Dr Josep Cornella at the Max-Planck-Institute für Kohlenforschung in Mülheim an der Ruhr, where he developed Ni-catalyzed C-O bond formations using nitrous oxide. He came back to France to start the Labcom HitCat, a joint lab between the company Seqens and the group of Prof. Géraldine Masson (CNRS). Since July 2022, he has joined Iktos as Senior Scientist – Deputy Lab Head, where he works on the installation, development and utilization of the Iktos Robotics Platform for AI-driven Drug Discovery.
